CAR T

Showing   of 10 results

CAR T illustration

Novel Strategy to Improve CAR T-cell Efficacy in Non-Hodgkin Lymphoma Revealed in Preclinical Studies

University Hospitals Seidman Cancer Center researchers part of team finding blocking a single receptor may combat T cell dysfunction associated with poor response to therapy - Innovations in Cancer | Summer 2022

Team Led by UH Seidman Cancer Center Researcher Develops and Validates Three-in-One CAR T Therapy

Approach detailed in the journal Nature Communications shows therapeutic potential of BAFF CAR T for treating multiple B cell cancers, using mouse models with high effectiveness and minimum side effects - Innovations in Cancer | Winter 2022

CAR T illustration

Anti-CD19 CAR T-Cells Produced Locally at UH Seidman Cancer Center Induce High Remission Rates in B-cell Malignancies, Study Finds

Clinical trials published in Nature Communications detail advantages of local approach - Innovations in Cancer | Fall 2021

CAR T illustration

Multiple Myeloma Patients at UH Seidman Cancer Center First in Ohio to Receive New CAR T-Cell Therapy

Patients also have access to promising clinical trial of vactosertib and pomalidomide - Innovations in Cancer | Summer 2021

Mesothelin - positive

New Immunotherapy Center at UH Seidman Cancer Center Sets the Stage for Solutions

Center offers dozens of clinical trials, including soon a rare all-human protein CAR T trial for patients with certain hematologic malignancies - Innovations in Cancer | Winter 2021

CAR T cells

More Specific Approach to CAR T Cell Therapy Shows Promise for B Cell Cancers

Investigational New Drug (IND) authorization is under way - Innovations in Cancer | Fall 2020

Local Manufacture of CAR T Cells Achieving Promising Results for Patients with High-Risk Lymphomas

UH Seidman Cancer Center team can culture cells in just eight days - Innovations in Cancer | Winter 2020

UH Seidman is Actively Enrolling Patients in CAR-T Clinical Trials

UH Seidman Cancer Center Update | October 2019

Results are loading...